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Abstract
As with other chronic conditions, adherence to daily medications remains a challenge for many individuals living with HIV due to
structural, behavioral, and social barriers. Unfortunately, high levels of adherence to antiretroviral therapy are required to
maintain virologic suppression. Alternative approaches are being explored to decrease the burden of daily pill administration,
including long-acting injectable, oral, and implantable products. Phase 3 data support the efficacy of nanoformulated injectable
cabotegravir and rilpivirine for HIV treatment in patients with undetectable viremia, but we have yet to learn how this strategy
may benefit those with medication adherence challenges. Despite this, the affected community and HIV providers are very
interested in exploring the role of long-acting therapies to address some types of barriers to medication adherence. This
review summarizes available information about the potential for long-acting therapy to improve adherence for some patients
and outlines associated opportunities and challenges with the implementation of long-acting therapy for the treatment and
prevention of HIV.
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For many chronic conditions, long-acting (LA) medication
therapies have improved medication adherence compared to
daily oral therapy, leading to improved clinical outcomes. The
term LA has been used in drug delivery to describe applications
for multiple routes of administration, including oral, topical
and parenteral, which includes intravenous, intramuscular, sub-
cutaneous injections, and implantable devices. Generally, it is
proposed that to be considered a LA therapy, an oral drug
should achieve at least once weekly dosing, an injection at least
monthly, and an implant at least 6-monthly dosing.1 Existing
LA drugs have specific pharmacokinetic and pharmacody-
namic properties that make them compatible with this
approach. In addition to the need for a favorable safety profile,
formulation of LA drugs requires low aqueous solubility
(water-soluble drugs dissolve rapidly and release drug), high
potency (to minimize the requirement for high plasma concen-
trations), and a long pharmacokinetic half-life (to minimize
rapid clearance).1
Contraception is one example of improving therapy effec-
tiveness with LA delivery. Options for contraceptive hormone
delivery include daily oral pills, weekly topical patch, monthly
vaginal rings, quarterly injection, and implants or intrauterine
devices (IUD) approved for use years after placement. In one
study of nearly 7500 women, individuals using LA reversible
contraception (injection, implant or IUD) had a 20-fold lower
risk of pregnancy (hazard ratio 20.1, 95% CI 13.7-34.9).2 This
improvement in effectiveness is related to both adherence to,
and continuation of, the contraceptive.3 In addition to high-
lighting that less-frequent administration can improve medica-
tion adherence, contraception is an example of how patient
choice related to medication delivery can improve therapeutic
outcomes through shared decision making.
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Bisphosphonate therapy for osteoporosis also offer LA oral
and injectable therapy to overcome challenges to daily oral
adherence.4 Related to both adherence and persistence on ther-
apy, weekly oral therapy and less frequent injectable therapy
perform better than daily oral therapy.5-8 Adherence to once
yearly intravenous zolendronic acid, measured as proportion of
days covered (PDC), was higher compared to quarterly intra-
venous ibandronate (82% vs 60%, p < 0.0001).9 In a 24-month
clinical trial of annual infusions vs. weekly oral therapy, 74.2%
of individuals preferred yearly therapy compared to 15.3%who
preferred weekly dosing, illustrating that patients often desire
as infrequent of administration as possible.10
For patients with structural, behavioral, or cognitive barriers
to medication adherence, LA therapy is a useful strategy to
overcome some of these barriers. For patients with schizophre-
nia, it is reported that up to two-thirds of individuals are par-
tially non-adherent to oral therapies, resulting in increased risk
of hospitalization for relapse.11 Compared to oral agents, LA
injectable antipsychotics are associated with lower risk of
relapse, fewer hospitalizations, and greater retention on ther-
apy.11-13 In addition, one study found that individuals who
were nonadherent to oral antipsychotics were less likely to
discontinue LA therapy (p ¼ 0.033) compared with patients
on oral therapy.14
Building upon success in these disease states, LA antiretro-
virals are currently being developed for the treatment and pre-
vention of HIV infection. Although access to and linkage to
care for the treatment of HIV is critical, it is less likely to be
influenced by the choice of prescribed medications. Therefore,
herein we address treatment adherence defined as retention in
care (i.e. attending clinic visits as scheduled) or medication
adherence (i.e. taking the dose and frequency of medication
as prescribed). In this review, we summarize these emerging
therapies, with an emphasis on the role of LA therapy to
address some barriers to medication adherence and to inform
the implementation of LA therapy for HIV into clinical
practice.
Ethical Approval and Informed Consent
Ethical approval and informed consent were not required as
this manuscript is a review of previously published data.
LA Antiretroviral Therapy for HIV Infection
Modern antiretroviral therapy (ART), featuring 2 to 3 antire-
troviral agents from at least 2 different antiretroviral classes,
has transformed HIV infection into a long-term, chronic med-
ical condition.15 ART reduces HIV-associated morbidity and
mortality, leading to a similar life expectancy to their peers for
patients with HIV.16 Contemporary oral ART is extremely
effective at suppressing HIV viremia, often with once daily
single tablet dosing and minimal toxicity.15 So why do we need
LA formulations as an alternative? Adherence to lifelong daily
therapy is challenging for many patients.15 A small proportion
of patients with HIV have trouble swallowing pills or absorbing
them, but very many express fatigue at the relentless demands
of daily pill taking, without an end in sight.17,18Other barriers to
adherence include internal and external stigma, low health lit-
eracy, financial barriers, mental health/substance use disorders,
or competing priorities related to life events, caregiving, or
unstable housing.15 Many of these barriers cannot be overcome
through choice of medication, but multiple investigational or
reformulated LA antiretroviral agents are in development for
the treatment and prevention of HIV to provide potential alter-
natives related to pill taking barriers and importantly, offer
patient choice in their preferred route of medication adminis-
tration (Table 1).19 An alternative LA delivery system may
offer several advantages, including relief from the “pill fatigue”
endorsed by many patients20 (Figure 1) and better protection of
health privacy, which is particularly relevant for people with
HIV who may experience stigma.21
The first long-acting, complete ART regimen includes
injectable formulations of cabotegravir, an integrase strand
transfer inhibitor, and rilpivirine, a non-nucleoside reverse
transcriptase inhibitor. This 2-drug combination has completed
phase 3 trials,22,23 and is approved in Canada,24 by the Eur-
opean Medicines Agency,25,26 and the US Food and Drug
Administration.27 However, whether or not this strategy will
improve adherence to antiretroviral therapy in patients with
specific barriers to adherence has yet to be established.
LA Cabotegravir with Rilpivirine for the Treatment of HIV
The phase 3 randomized trials of cabotegravir and rilpivirine
included patients with HIV naı̈ve to ART (FLAIR) and those
with antiretroviral treatment experience, but virally suppressed
on an oral ART regimen (ATLAS).22,23 The FLAIR study
required a 6-month oral induction phase to achieve virologic
suppression prior to receipt of the LA injection,22 and ATLAS
had a 4-week lead-in to ensure tolerability of oral cabotegravir
and rilpivirine prior to injection.23 The drugs require a loading
dose of 600 mg and 900 mg, cabotegravir and rilpivirine
respectively, by two 3 mL injections (one into each gluteus
medius muscle), followed by maintenance doses of 400 mg
and 600 mg given as 2, 2 mL injections every 4 weeks. Both
studies demonstrated that monthly injections of cabotegravir
and rilpivirine were noninferior to continued oral ART, based
on detectable viral load at Week 48 (plasma HIV-1 RNA  50
copies/mL pooled results: 1.9 vs 1.7%).22,23 Collectively, both
studies had 591 participants in each arm (injectable therapy
versus continuing oral therapy). Of note, 6 of 7 participants
with confirmed virologic failure in the Phase 3 trials who
received injectable cabotegravir and rilpivirine, had resistance
mutations detected at the time of failure, in contrast to 3 of the 7
participants with virologic failure on oral therapy.28 The parti-
cipants with virologic failure on injectable therapy also had
non-clade B subtype HIV (A6, A1, and AG); an area requiring
further study.
Serious adverse events were rare in both trials (4%), but
injection site reactions were common in the injectable arms
(80%).22,23 As the injection site reactions were generally mild
























































































































































































































































































































































































































































































































































































































































































and short-lived (median duration 3 days), these rarely led to
treatment discontinuation. Firsthand observations from our
own patients is that they anticipate some mild discomfort after
the injections and may make adjustments to their schedules or
planned activities, but generally find the injections very man-
ageable. The ongoing ATLAS-2M trial is evaluating injections
every 2 months compared to monthly, which will halve the
number of injections, and potential injection site reactions.29
The European Medicines Agency approved LA cabotegravir
and rilpivirine for administration either monthly or every 2
months based on preliminary ATLAS-2M results,25,26 and
approval of the every 2 month option is anticipated in both
the US and Canada in the future.
So, who may benefit from this strategy if it becomes avail-
able? Phase 3 trial participants were non-pregnant adults with
well controlled HIV disease, generally normal renal and hepa-
tic function, and limited comorbidities. Only one prior regimen
switch was permitted prior to entry into the ATLAS trial.29
Hepatitis B coinfection was exclusionary for both studies, as
cabotegravir and rilpivirine are not effective treatment options
for hepatitis B chronic infection like some other antiretrovirals.
Particular efforts were made to enroll women into the trials,
resulting in 27.5% all participants being women.22,23 However,
overall, only 29% of all participants were non-white. Conse-
quently, data are lacking for children and adolescents, pregnant
people, those with impaired organ function, and most impor-
tantly perhaps, those with poorly controlled HIV disease. An
ongoing trial for this key population with barriers to adherence
is described in more detail below. Until results from this study
is available, we can only conclude that LA antiretroviral ther-
apy may provide a very welcome alternative to daily oral ther-
apy for the many people with HIV who fit the entry criteria for
the phase 3 trials.
Additional Lessons Learned from HIV Pre-exposure
Prophylaxis (PrEP) Studies
In 2010, oral emtricitabine with tenofovir disoproxil fumarate
(FTC/TDF) was shown to provide protection against the acqui-
sition of HIV infection in a seminal study of 2499 HIV-
seronegative men who have sex with men or transgender
women.30 When compared to placebo, FTC/TDF reduced HIV
incidence by 44% (95% confidence interval, 15 to 63; P ¼
0.005). Protection would have been closer to 90% though, if
the analysis were restricted to participants with drug detected at
any concentration in blood.31Only 55% of participants tested at
week 8 had drug detected, and detectable drug in blood plasma
or peripheral blood mononuclear cells was less frequent in the
incident HIV cases compared to uninfected controls (8% vs
44%, P < 0.001), highlighting the importance of medication
adherence.
More recently, the HPTN083 study evaluated LA cabote-
gravir given by intramuscular injection every 8 weeks com-
pared to daily oral FTC/TDF in a phase 2b/3 randomized,
double-blind, double-dummy trial.32 4750 adult men who have
sex with men and transgender women were enrolled at 43 sites.
The Data Safety Monitoring Board (DSMB) stopped the study
early after a total of 52 HIV infections had occurred: 13 infec-
tions in the cabotegravir arm (incidence rate 0.41%) and 39
infections in the FTC/TDF arm (incidence rate 1.22%). The
hazard ratio in the cabotegravir versus FTC/TDF arms was
0.34 (95% CI 0.18-0.62), corresponding to a 66% reduction
in incident HIV infections in study participants given cabote-
gravir compared to FTC/TDF. While the study had a non-
inferiority design, these results met the statistical criteria for
superiority of the regimen containing cabotegravir compared to
FTC/TDF. HPTN 084 has a similar design but enrolled cisgen-
der women. This trial was also recently halted early by the
OPPORTUNITIES
• Less frequent dosing
• Avoidance of “pill fatigue”
• Oral dosing by-passed; bioavailability ~100%
• Less adverse events
• Less drug-drug interactions
• Protection of health privacy
• Avoidance of HIV-related stigma
• Improved adherence?
CHALLENGES
• Large injection volumes
• Need for oral lead in
• Management of missed doses
• Coverage of the “tail”
• Development of drug resistance
• Management of drug-drug interactions
• Management of serious adverse events
• Unknown dosing for children & pregnant women
Figure 1. Long-acting antiretroviral therapy: potential opportunities and challenges.
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DSMB.33 A total of 40 HIV infections occurred during follow-
up, with 4 infections in the cabotegravir LA arm (incidence rate
0.2%) and 36 infections in the FTC/TDF arm (incidence rate
1.86%). The hazard ratio in the cabotegravir LA versus FTC/
TDF arm was 0.11 (95% CI 0.01-0.31), meaning 89% reduc-
tion. Although pharmacokinetic analysis of stored samples are
currently underway to assess medication adherence, it is a rea-
sonable hypothesis that this improvement in effectiveness is
related to the difference in adherence between oral and inject-
able therapy. Overall, these results provide a clear demonstra-
tion of the benefits of an LA formulation as compared to
standard oral daily dosing for HIV pre-exposure prophylaxis.
Further, the availability of multiple, highly effective HIV pre-
vention products is expected to increase patient uptake and
persistence due to patient preference for the delivery method,
similar to the role of choice in hormonal contraception.2
Challenges with Long-Acting Therapy
The logistical challenges associated with rolling out LA strate-
gies for ART in healthcare systems throughout the world will
require planning and preparation due to the change inmedication
provision and tracking compared to oral therapies. Other poten-
tial challenges include the need for an oral lead-in, the manage-
ment of missed doses, and the long pharmacokinetic tail.
Implementation in HIV clinics. At present, the injection requires
two 3 mL injections for the loading dose24-27 and for every
8 week maintenance injections as investigated in ATLAS-
2M,25,26 or two 2 mL injections for every 4 week maintenance
injections,24,27 which must be injected into the gluteus medius
muscles. The co-packaged product requires refrigeration and
must be brought to room temperature prior to injection and then
used within 2 hours of being drawn into the syringe for injec-
tion.27 Given this process, initial steps for administering LA
cabotegravir and rilpivirine include clinic staff training, plan-
ning for clinic workflow and patient scheduling, cold chain
management, and drug product acquisition, storage and
inventory.
Ongoing monthy or bimonthly visits to the clinic will be a
new procedure for both patients and providers. From the clinic
perspective, this will increase staffing requirements as well as
introduce adherence monitoring requirements to ensure
patients are returning on schedule for the injection visit. From
the patient perspective, this may increase time away from work
or personal responsibilities to attend injection appointments.
Preliminary data from a study involving healthcare workers
(“staff participants”) involved in clinical trials at 8 clinics in the
US reported that at baseline, staff participants most frequently
had concerns about the ability of patients to adhere to monthly
visits, patient transportation, and the clinic’s ability to flag
missed visits. All of the concerns decreased by month 4 after
implementation, highlighting that many of the challenges can
be addressed through planning and training.34 In addition, for
clinics that are not able to accommodate additional visits
for injections, the manufacturer is offering alternative options
for medication administration, including an “Alternate Site for
Administration” locator in the US via the manufacturer’s web-
site (https://www.viivconnect.com/injectable/). Additional
implementation strategies are under investigation, including
pharmacy-based administration, which may offer the advan-
tage of injection appointment times outside of traditional clinic
hours.
Need for oral lead in. All the clinical trials of LA cabotegravir
and rilpivirine thus far, both for treatment and prevention of
HIV, have included a 4-week oral lead-in (OLI) phase to ensure
that the drugs are well tolerated. Emerging data suggest that
this may not be necessary, as no safety signals were observed in
any of the studies.22,23,29 In an extension to the FLAIR study,
participants originally randomized to oral therapy who wanted
to start injections were given the option of starting immediately
without an oral lead-in.35 111 participants opted to start injec-
tions directly (referred to as “Direct To Injection” or DTI) and
121 chose the OLI. The 2 groups had similar demographics
except that more White participants opted for DTI (78%
DTI vs 69% OLI) and more Black participants chose the OLI
(17% DTI vs 21% OLI). 24 weeks after the switch, 99.1% of
participants in the DTI group had undetectable viremia com-
pared to 93.4% in the OLI group. Incidence of drug-related
adverse events was the same in both groups, approximately
20%, with only one serious event (Hodgkin lymphoma, not
related to the intervention). Taken together, these data support
the DTI approach in individuals with virologic suppression,
which would remove one of the barriers to starting LA inject-
able therapy, but is not yet approved by regulatory agencies.
Management of missed doses. A major concern for both provi-
ders and patients about implementation of a LA injectable
strategy for HIV treatment is the consequences of missed
doses. In the Phase 3 trials, a window of þ/- 7 days was per-
mitted for receipt of the injections, and 98% of participants
were able to meet this timeline.36 The alternate approach for
those who could not attend the injection visit was to provide
them with oral versions of the study drugs to tide them over to
the next injection, referred to as oral “bridging”, and informed
by pharmacokinetic modeling studies.37,38 The recommenda-
tions in package inserts are consistent with these modeling
results: within 7 days of a scheduled visit, the injections can
be administered as planned, while a planned absence more than
7 days beyond the scheduled injection requires oral bridging,
and a clinical assessment upon return for any patient who has
an unplanned absence without oral bridging.24,27 Based on the
modeling data, when injections are resumed, if  2 months
elapsed since the last injection, injectable maintenance doses
can be reinstated.37,38 If more than 2 months have elapsed,
loading doses should be given, followed by resumption of
maintenance dosing.
While this is a useful guide to managing missed or delayed
doses, uncertainties remain related to the practicality of this
approach outside of a clinical trial setting. For example, in the
United States, oral cabotegravir is not available in retail
Scarsi and Swindells 5
pharmacies. Therefore, patients and providers must plan ahead
for any disruption in the dose administration schedule to access
oral cabotegravir from the manufacturer and oral rilpivirine
from a retail pharmacy.13 Delayed or missed doses are often
unplanned in real-world settings, which may not allow suffi-
cient time to access oral cabotegravir. One practical strategy
may be to provide oral bridging with another commercially
available antiretroviral combination that is accessible at a local
pharmacy, or that the patient may already have on hand at
home, such as co-formulated dolutegravir and rilpivirine.
Implications of the pharmacokinetic “Tail”. As discussed above,
one of the key characteristics of drugs suitable for LA formula-
tion is a long half-life. How long the drug persists after final
administration is often referred to as the pharmacokinetic
“tail”. The reported half-life of LA cabotegravir is 20–65 days,
and the half-life of LA rilpivirine is 30–90 days, and concen-
trations of both have been detected in some patients up to 1
year after the last injection.39-43 HPTN 077 was a placebo-
controlled phase IIa trial to evaluate the safety and pharmaco-
kinetics of LA cabotegravir for prevention of HIV.43 A
prespecified analysis focused on the pharmacokinetic tail phase
after the last IM dose.44 At 52–60 weeks after the last injection,
23% of men versus 63% of women still had detectable cabote-
gravir concentrations; at 76 weeks, these rates were 13% of
men versus 42% of women. The mean time from last dose
to undetectability was much longer for women than for men
(67.3 vs. 43.7 weeks). Higher body-mass index was also asso-
ciated with a significantly longer terminal phase half-life.
However, less than 10% of the variability in the tail was
explained by sex and BMI, emphasizing the need for more
investigation into this issue.
This long half-life support the ATLAS-2M dosing every
2 months and may be a significant advantage for individuals
with adherence challenges. However, this may also pose a
potential problem in that, after discontinuation of the drug,
patients are exposed to decreasing concentrations over time,
which will eventually fall below the effective threshold for
either HIV prevention or virologic suppression during HIV
treatment. In the setting of HIV infection, this may be a setup
for the development of virologic resistance, as we have
observed with other long half-life antiretroviral medica-
tions,45-47 and in the prevention setting, represents a period
of risk for HIV acquisition for patients at risk for HIV infection.
For patients who remain engaged in clinical care, a solution to
cover the tail is to transition to alternative oral ART or PrEP
therapy, but this represents a substantial challenge for patients
who are lost to follow-up.
Patient Preferences and Concerns
Several surveys have demonstrated patient interest in LA for-
mulations for the treatment of HIV. Participants in the phase
3 trials of LA cabotegravir and rilpivirine expressed high levels
of treatment satisfaction, even after the experience of 2, 2 mL
gluteal injections every month.48 In qualitative studies, some
expressed a sense of “freedom” from the logistical and psycho-
social demands of daily oral therapy and its attendant
stigma.49,50 In qualitative interviews, trial participants from the
US and Spain reported that the LA therapy was convenient,
increased confidentiality and privacy, and had fewer opportu-
nities for stigma, discrimination, or disclosure of HIV status
because of daily pill taking.21,49
In addition to clinical trial participants, several studies have
found a high level of interest in LA therapies in adults and
adolescents living with HIV who have not participated in LA
clinical trials. Two studies of 374 and 400 adults with HIV,
found 61% and 73%, respectively, of adults would be likely or
very likely try LA ART.51,52 In 303 youth aged 13 to 24 years,
88.1% reported that they would probably or definitely try a LA
injectable ART option.53 This interest persists outside of the
US, one study of 409 female sex workers found that 92% of
participants in Tanzania and 85% of participants in Dominican
Republic would be very likely or likely to use a LA ART.54 In
qualitative interviews and surveys, participants cited discre-
tion, convenience, confidentiality, reducing pill burden, remov-
ing fear of missed dosing, and avoiding daily reminders of
living with HIV which led to a feeling of normalcy.51,55,56
However, some concerns about a switch from oral therapy to
LA ART were also reported, including comfort with their cur-
rent oral regimen, known effectiveness of oral options, poten-
tial differences in adverse effects between LA and oral
formulations, and personal control over daily oral dos-
ing.52,55,57 When considering injectable therapy, some con-
cerns were identified in survey respondents specifically
related to the injection (Figure 2).51 Some participants also
raised concern that additional visits to the clinic required for
LA ART administration may be a source of potential stigma/
discrimination due to time away from work or if they have not
disclosed their HIV status to friends or family members.21,49
Some studies provide insight into patient characteristics
which may predict those individuals who could have the most
adherence benefit from LA therapy. Participants who require
other daily oral medications did not view replacing oral ART
with an injectable option as beneficial compared to those who
did not have other routine oral medications. One survey found
that patients who did not report any missed oral doses were
most concerned with disrupting their established medication
administration routine with a switch to LA therapies.52 Finally,
it remains uncertain if patients who have difficulty attending
clinic visits are good candidates for LA ART. One study iden-
tified participants who struggle to attend clinic actually pre-
ferred LA therapies over oral pills,51 yet there are obvious
concerns surrounding missed LA doses if patients cannot
attend clinic visits related to the prolonged pharmacokinetic
tail, as discussed above.
In total, the positive qualities of LA ART identified in both
phase 3 clinical trial and in other studies suggest that LA ART
offers an important option for patients to choose, which may
overcome some barriers associated with medication adherence.
Certainly LA therapies cannot overcome all barriers to
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adherence and some patients may find additional challenges
associated with LA therapies.
Long-Acting Therapy in the Setting of Adherence Barriers
Long-acting therapies are one tool which may improve adher-
ence to ART for some individuals, particularly those with
adherence barriers related to pill-fatigue or pill-aversion.
Modeling suggests that LA ART may be most cost-effective
in those individuals with barriers to adherence to daily oral
therapy.58 However, given the high adherence to injectable
therapy observed in Phase 3 trials of LA cabotegravir and
rilpivirine, practical questions exist surrounding the effective-
ness of LA therapies beyond clinical trials.
Initial data from the LA cabotegravir and rilpivirine com-
passionate use program describe 35 individuals who qualified
for the program.59 Of the participants, most were enrolled due
to barriers to oral medication adherence, including difficulty
with pill swallowing, pill fatigue, and stigma, the remaining
were eligible based on physical, psychological, and cognitive
challenges. Of the 28 who entered the program with detectable
viremia, 16 (57%) achieved virologic suppression (HIV-1 RNA
< 50 copies/mL). Six of 7 participants who enrolled with a
suppressed HIV RNA maintained virologic suppression on
LA cabotegravir and rilpivirine. Five (14%) patients had
incomplete virologic responses and stopped the injectable
treatment. Four of these patients had NNRTI resistance-
associated mutations at failure and 2 had integrase inhibitor
resistance-associated mutations. These early data demonstrate
LA therapy will be a viable option for many patients who
struggle with daily oral ART adherence, but the 14% of parti-
cipants with virologic failure demonstrate the ongoing impor-
tance of addressing barriers to adherence.
The AIDS Clinical Trials Group (ACTG) study A5359, the
LATITUDE study, is a Phase 3, randomized clinical trial in 350
patients with a history of non-adherence. The LATITUDE study
will compare the efficacy, safety, and durability of standard of
care oral ART to LA cabotegravir/rilpivirine given IM every 4
weeks (NCT03635788). The trial will include participants with
non-adherence to oral therapy which resulted in virologic failure,
as well as those who were lost to clinical follow-up. To support
patients through the oral lead in period (6 months to achieve
virologic suppression), the trial will utilize conditional economic
incentives, a strategy that improved adherence, retention in care,
and virologic suppression in other studies of oral ART,60-62 in
addition to other adherence interventions supported by clinical
guidelines.15,63 Other implementation trials of LA cabotegravir
and rilpivirine are limited to patients without prior virologic
failure, irrespective of resistance (NCT04001803,
NCT04399551). Therefore, results from the LATITUDE trial
will improve our understanding of how to support adherence
to the oral lead-in therapy, as well as the long-term role of LA
injectable therapy, compared to standard of care in an important
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Figure 2. Concerns regarding long-acting injectable antiretroviral therapy. Among 371 participants who indicated if they were willing to try LA
ART, differences were found in the frequency of concerns identified between those willing and unwilling to receive LA ART. Adapted from
Dandachi et al. AIDS Care 2020.51
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Other Long-Acting Antiretroviral Strategies
Although intramuscular injectable LA therapy is now available
for HIV treatment and on the horizon for HIV prevention, other
methods for LA drug delivery are at various stages of devel-
opment (Table 1). Ibalizumab, a monoclonal antibody that is a
CD4 cell directed post-attachment entry inhibitor, was the first
LA therapy approved by the US FDA for highly treatment
experienced patients.64 Ibalizumab is administered twice
weekly as an infusion over 15-30 minutes, but must be used
in combination with other oral antiretrovirals. Encouragingly,
the LA medications in development span all of the classes of
antiretrovirals, which raises hope for a future of multiple fully-
suppressive LA therapies for both prevention and treatment of
HIV, including for those individuals who are highly treatment
experienced.
Other routes of LA drug administration may address some
of the challenges with IM LA therapy. For example, an oral or
subcutaneous injection product given once weekly would allow
for self-administration, which some patients may prefer to
either avoid inconvenience or stigma related to frequent visits
to the provider, or to offer individual control over their dose
administration. Implantable products hold the potential for a
removable LA product in case of an adverse effect and also
may address patient concerns related to prolonged exposure to
therapy after discontinuation. These different routes of admin-
istration, and certainly products with a longer duration of
action, may also ease the burden of frequent clinic visits for
dose administration for both providers and patients. Consis-
tently, less frequent administration of LA therapies was asso-
ciated with greater interest by patients across disease
states.21,49,53,57
Conclusion
Long-acting antiretroviral therapy is an exciting area of inves-
tigation and may provide a welcome alternative for patients to
both prevent and treat HIV infection. Current data support the
efficacy and safety of the first complete LA ART regimen,
cabotegravir and rilpivirine, in nonpregnant adults with demon-
strated HIV virologic suppression, absence of hepatitis B coin-
fection, and normal renal and liver function. Many providers
and patients are interested to learn how this approach might
help those with adherence challenges, but more data from clin-
ical trials including this at-risk population and from real-world
clinical experience are needed before any conclusions can be
drawn. In addition to this key population, application to pedia-
tric populations and pregnant women should be explored. LA
therapies offer a key difference to currently available ART
regimens: patient choice related to their preferred way to
administer medications. Based on other disease states with
multiple routes of administration of available therapies, this
may lead to improved adherence and retention in care for some
patients. However, caregivers must consider all of the social,
structural, and behavioral barriers which may impact patient
adherence to both medication and clinical care which may not
be addressed by a change from oral to LA therapies. Overall,
provider-patient partnership and communication prior to any
change in ART to assure patient comfort with efficacy, adverse
effects, and administration requirements, as well as innovative
strategies to administer LA therapy at convenient times and
locations, will add to the benefits associated with removing
adherence barriers through LA ART.
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